From December 7th to 8th, 2023, the INNOXbio2023 Biomedical Industry Ecosystem Conference and the first Greater Bay Area Cell and Gene Development Forum were held in Guangzhou. to the research of new technologies to carry out all-round **. Dr. Zhang Lei, deputy general manager of Boyaa Stem Cell, delivered a speech entitled "Stem Cell Technology Development Trend and Prospects" at the sub-forum of "Stem Cell Technology and Organoid Technology", and worked with the guests to promote industrial innovation and development, and jointly build a new ecology of cell genes.
INNOXbio2023 Biomedical Industry Ecosystem Conference and the First Greater Bay Area Cell and Gene Development Forum were grandly held, as the most important "new track" in the global biomedical industry competition, "cell and gene" and clinical transformation have become a major topic in the development of health security in China during the 14th Five-Year Plan. In the Greater Bay Area, the cell and gene industry is developing rapidly and has become an important industry in the region. In 2022, the "14th Five-Year Plan for Science and Technology Innovation in Shenzhen" has listed cells and genes as one of the eight future industries in Shenzhen, and the biomedical industry as one of the emerging industries in Shenzhen's "20+8" industrial cluster. The convening of this conference is a vivid practice of making every effort to promote the construction of the Greater Bay Area. As a characteristic business card of China's cell industry, Boya Life has had a positive impact on the cell and gene industry in the Guangdong-Hong Kong-Macao Greater Bay Area with its innovative model of "automated medical devices-life bank-cell industry R&D and industrial application".
In this conference, Dr. Zhang Lei said, "Cell ** holds up a new pillar of future medicine, and realizes the medical transformation of 'life ** with life' through tissue repair, structural reconstruction and functional remodeling, which is an important carrier of precision medicine." The precision medicine model emphasizing "personalized medicine" has brought revolutionary changes to human health. With the research and development of drugs and technologies, as well as the increasing demand for personalized medicine in clinical practice, the empowerment of autologous cell "sample bank and resource bank" will become a key element in the development of precision medicine. In 2023, Boyaa Stem Cell, a subsidiary of Boyaa Life, will rebuild its positioning as a "clinical-grade family cell asset and health management laboratory", and is committed to providing a support service platform for the development of precision medicine. At the same time, in 2023, Shenzhen Boya Perception Pharmaceutical, a subsidiary of Boyaa Life, will independently develop a class I biological product "Huatong's Gel Mesenchymal Stem Cell Injection"."(Acceptance number: CXSL2200587), which has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, has added an important engine to the development and practice of precision medicine in the Greater Bay Area.
Dr. Zhang Lei, Deputy General Manager of Boyaa Stem Cell, was invited to give a keynote speech at the INNOXbio2023 Biomedical Industry Ecosystem Conference and the first Greater Bay Area Cell and Gene Development Forum.
In the report, Dr. Zhang Lei pointed out that "the dilemma faced by today's cell ** is that clinical accessibility has not yet been achieved, and technological innovation through different paths is needed to break the situation." This paper summarizes the current challenges of regenerative medicine, analyzes the development trend of stem cell technology, and looks forward to the future to inspire ideas for technological innovation. He believes that "access paths, cell ** and manufacturing costs are the current challenges for the development of cell products. In situ regeneration, spot cells, and customized cells are three key technology development trends. Cell + biomedicine, cell + synthetic biology, and cell + digital twin are the three major technological prospects". Boyaa Life is one of the earliest enterprises in China to lay out the first cell track, and has made extensive layouts in the fields of in-situ regeneration, large-scale cell industrial production and intelligent customized cells, and has promoted the transformation of the biomedical industry from multiple dimensions such as high-standard quality system, cell clinical research transformation, automated cell medical devices and technical services.
As one of the most economically active and developed regions, the Guangdong-Hong Kong-Macao Greater Bay Area is an important area where China's biomedical industry gathers, with a strong industrial foundation and excellent innovation ability, and has become a new highland for the development of China's cell and gene industry. In recent years, Boyaa Life has always taken the cutting-edge key technologies and services of cells as a breakthrough, and is committed to building an innovative ecosystem conducive to the high-quality development of biomedical industries such as cells and genes, helping the sustainable development of strategic emerging industries in the Guangdong-Hong Kong-Macao Greater Bay Area, and contributing to the protection of people's lives and health and the high-quality development of China's health industry.